Cardiac Magnetic Resonance Imaging, Focal or Diffuse Fibrosis, Idiopathic, Premature Ventricular Complexes, Structural Heart Disease, Ventricular Arythmias
Conditions
Keywords
premature ventricular complexes, ventricular arythmias, cardiac magnetic resonance, focal or diffuse fibrosis, structural heart disease, idiopathic
Brief summary
Premature ventricular complexes (PVC) are a common entity affecting approximatively 20% of the general population. It can be discovered incidentally on electrocardiogram (ECG) or associated with symptoms with a wide spectrum from palpitations, chest pain, to syncope. The initial and non invasive assessment includes holter ECG monitoring, a transthoracic echocardiography (TTE) and an exercise stress test to rule out structural heart disease (SHD), and referred to as benign or idiopathic ventricular arrhythmias (IVA). However, these exams may fail to identify subtle myocardial abnormalities such as arrhythmogenic right ventricle dysplasia (ARVD), apical hypertrophic cardiomyopathy, healed myocarditis, ischemic or non-ischemic cardiomyopathies. Cardiac magnetic resonance (CMR) imaging is the gold standard modality to assess regional and global ventricular function. It is also a unique modality to non-invasively detect myocardial edema, myocardial fatty replacement, focal and diffuse fibrosis and could potentially identify SHD in patients with PVC. However, the role of CMR is uncertain, recommended in case of atypical presentation or when the initial assessment can't exclude a cardiomyopathy (recommendations class IIa). This study sought to determine whether and when CMR can be performed to provide diagnosis or prognostic information complementary to initial assessment in patients referred for PVC by their cardiologists.
Interventions
None listed
Sponsors
Study design
Eligibility
Inclusion criteria
* patients with PVC who have performed ECG, Holter ECG and a CMR
Exclusion criteria
* patient showing opposition tu use his personal data for the reseach, * patient unable to express his opposition, * patient deprived of liberty, * patient with language issues (speaking or writing French)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of myocardial abnormalities identified by CMR | 1 day | Composite endpoint of myocardial abnormalities identified by CMR including dilated cardiomyopathy, hypertrophic cardiomyopathy, ischemic cardiomyopathy, ventricular non-compaction, ARVD, myocarditis, pericarditis, sarcoidosis, amyloidosis, Fabry disease |
Secondary
| Measure | Time frame |
|---|---|
| number of criteria to predict myocardial abnormalities on CMR | day 1 |
Countries
France